Drug Combination Details
| General Information of the Combination (ID: C35840) | |||||
|---|---|---|---|---|---|
| Name | Paclitaxel NP Info | + | 3'-azido-3'-deoxythymidine Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Pharynx tumor
[ICD-11: 2F90]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| In-vitro Model | FaDu | CVCL_1218 | Squamous cell carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Paclitaxel combinated with low and nontoxic AZT dose was a novel cancer therapeutic approach to human pharynx faDu cells. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Synergy between 3'-azido-3'-deoxythymidine and paclitaxel in human pharynx FaDu cells. Pharm Res. 2003 Jul;20(7):957-61. | |||
